New combo shows promise for myeloma patients who failed earlier therapy
NCT ID NCT04302324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or didn't respond after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors more effectively than standard options. The study involves 11 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine - Multiple Myeloma Center
New York, New York, 10065, United States